自身免疫性疱病与银屑病的相关性

doi:10.35541/cjd.20200162

Abstract

Abstract: 【Abstract】 There are overlaps in pathogenesis between autoimmune bullous diseases （AIBDs） and psoriasis. In recent years, there have been many reports on correlations between psoriasis and AIBDs. Bullous pemphigoid is the most common AIBD associated with psoriasis, followed by pemphigus vulgaris, pemphigus erythematosus and linear IgA bullous dermatosis. AIBDs occur after the onset of psoriasis in most cases, but simultaneously with or before the onset of psoriasis in some patients. This review summarizes correlations between AIBDs and psoriasis, as well as possible mechanisms.

Key words: Psoriasis, Skin diseases, vesiculobullous, Autoimmune diseases, Pemphigus, Pemphigoid, Bullous

Shan Ying, Zuo Yagang. Correlation between autoimmune bullous diseases and psoriasis[J]. Chinese Journal of Dermatology, 2022, 55(5): 452-455.doi:10.35541/cjd.20200162

References ［35］

［1］	Kridin K, Kridin M, Shalom G, et al. The coexistence of pemphigus and psoriasis: a systematic review and meta⁃analysis［J］. Immunol Res, 2019,67（1）:134⁃141. doi: 10.1007/s12026⁃018⁃9031⁃6.
［2］	Ho YH, Hu HY, Chang YT, et al. Psoriasis is associated with increased risk of bullous pemphigoid: a nationwide population⁃based cohort study in Taiwan［J］. J Dermatol, 2019,46（7）:604⁃609. doi: 10.1111/1346⁃8138.14902.
［3］	Kridin K, Zelber⁃Sagi S, Comaneshter D, et al. Association between pemphigus and psoriasis: a population⁃based large⁃scale study［J］. J Am Acad Dermatol, 2017,77（6）:1174⁃1175. doi: 10.1016/j.jaad.2017.07.007.
［4］	Phan K, Goyal S, Murrell DF. Association between bullous pemphigoid and psoriasis: systematic review and meta⁃analysis of case⁃control studies［J］. Australas J Dermatol, 2019,60（1）:23⁃28. doi: 10.1111/ajd.12899.
［5］	Wilczek A, Sticherling M. Concomitant psoriasis and bullous pemphigoid: coincidence or pathogenic relationship?［J］. Int J Dermatol, 2006,45（11）:1353⁃1357. doi: 10.1111/j.1365⁃4632. 2006.02861.x.
［6］	Ohata C, Ishii N, Koga H, et al. Coexistence of autoimmune bullous diseases （AIBDs） and psoriasis: a series of 145 cases［J］. J Am Acad Dermatol, 2015,73（1）:50⁃55. doi: 10.1016/j.jaad.2015.03.016.
［7］	Zhang X, Mao X, Theresia C, et al. Pemphigus associated with psoriasis vulgaris: a retrospective study of seven patients and a review of the literature［J］. Acta Dermatovenerol Croat, 2018,26（3）:226⁃232.
［8］	Kridin K, Ahmed AR. Anti⁃p200 Pemphigoid: a systematic review［J］. Front Immunol, 2019,10:2466. doi: 10.3389/fimmu.2019. 02466.
［9］	Zheng J, Liu N, Wang Y, et al. Pemphigus vulgaris with psoriasis vulgaris successfully treated with methotrexate and low⁃dose methylprednisolone［J］. Dermatol Ther, 2020,33（1）:e13165. doi: 10.1111/dth.13165.
［10］	Tsuchida Y, Hayashi R, Ansai O, et al. Generalized pustular psoriasis complicated with bullous pemphigoid［J］. Int J Dermatol, 2019,58（3）:e66⁃e67. doi: 10.1111/ijd.14332.
［11］	Claus S, Ziemer M, Simon JC, et al. Coincidence of annular pustular psoriasis, pemphigus foliaceus, and leukocytoclastic vasculitis associated with chronic cholecystitis［J］. J Dtsch Dermatol Ges, 2016,14（8）:830⁃831. doi: 10.1111/ddg.12619.
［12］	Fujimura Y, Natsuga K, Hamade Y, et al. Anti⁃laminin⁃gamma 1 pemphigoid with generalized pustular psoriasis and psoriasis vulgaris［J］. Acta Derm Venereol, 2016,96（1）:120⁃121. doi: 10. 2340/00015555⁃2168.
［13］	Nin M, Tokunaga D, Ishii N, et al. Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept［J］. J Dermatol, 2013,40（1）:55⁃56. doi: 10.1111/j.1346⁃8138.2012. 01659.x.
［14］	Furue K, Ito T, Tsuji G, et al. Autoimmunity and autoimmune co⁃morbidities in psoriasis［J］. Immunology, 2018,154（1）:21⁃27. doi: 10.1111/imm.12891.
［15］	Becker JG, Mundi JP, Newlove T, et al. Development of linear IgA bullous dermatosis in a patient with psoriasis taking ustekinumab［J］. J Am Acad Dermatol, 2012,67（4）:e150⁃e151. doi: 10.1016/j.jaad.2011.11.955.
［16］	Fujimoto N, Matsuo S, Satoh T. Psoriasis vulgaris in a patient with pemphigus vulgaris on corticosteroid therapy［J］. J Dtsch Dermatol Ges, 2018,16（5）:606⁃608. doi: 10.1111/ddg.13505.
［17］	Dainichi T, Kabashima K. Interaction of psoriasis and bullous diseases［J］. Front Med （Lausanne）, 2018,5:222. doi: 10.3389/fmed.2018.00222.
［18］	Rosmaninho A, Oliveira A, Sanches M, et al. IgA pemphigus and pustular psoriasis: a possible relation［J］. Eur J Dermatol, 2011,21（1）:100⁃101. doi: 10.1684/ejd.2011.1159.
［19］	Ohashi M, Takagi H, Mizutani Y, et al. Bullous pemphigoid with IgG autoantibodies to the α3 subunit of laminin 332 associated with psoriasis vulgaris［J］. Eur J Dermatol, 2017,27（3）:306⁃307. doi: 10.1684/ejd.2017.2980.
［20］	Natsumi A, Sugawara K, Yasumizu M, et al. Re⁃investigating the basement membrane zone of psoriatic epidermal lesions: is laminin⁃511 a new player in psoriasis pathogenesis?［J］. J Histochem Cytochem, 2018,66（12）:847⁃862. doi: 10.1369/002 2155418782693.
［21］	Minakawa S, Matsuzaki Y, Hashimoto T, et al. Dipeptidyl peptidase⁃4 inhibitor⁃associated anti⁃laminin⁃γ1 （p200） pemphigoid in a patient with psoriasis vulgaris［J］. J Dermatol, 2020,47（1）:e25⁃e26. doi: 10.1111/1346⁃8138.15126.
［22］	Maglie R, Hertl M. Pharmacological advances in pemphigoid［J］. Curr Opin Pharmacol, 2019,46:34⁃43. doi: 10.1016/j.coph.2018. 12.007.
［23］	Yasukawa S, Dainichi T, Kokuba H, et al. Bullous pemphigoid followed by pustular psoriasis showing Th1, Th2, Treg and Th17 immunological changes［J］. Eur J Dermatol, 2009,19（1）:69⁃71. doi: 10.1684/ejd.2008.0572.
［24］	Pezzolo E, Naldi L. Epidemiology of major chronic inflammatory immune⁃related skin diseases in 2019［J］. Expert Rev Clin Immunol, 2020,16（2）:155⁃166. doi: 10.1080/1744666X.2020. 1719833.
［25］	Hirata J, Hirota T, Ozeki T, et al. Variants at HLA⁃A, HLA⁃C, and HLA⁃DQB1 confer risk of psoriasis vulgaris in Japanese［J］. J Invest Dermatol, 2018,138（3）:542⁃548. doi: 10.1016/j.jid.2017.10.001.
［26］	Vázquez⁃Osorio I, González⁃Delgado S, Suárez⁃García C, et al. Blisters induced by PUVA: a report of 5 cases［J］. Actas Dermosifiliogr, 2018,109（8）:e11⁃e16. doi: 10.1016/j.ad.2017. 10. 011.
［27］	Miyamoto D, Santi CG, Aoki V, et al. Bullous pemphigoid［J］. An Bras Dermatol, 2019,94（2）:133⁃146. doi: 10.1590/abd1806⁃4841.20199007.
［28］	Wilmer EN, Becker N, Chen A, et al. Etanercept⁃induced generalization of chronic, localized, anogenital bullous pemphigoid in a psoriatic patient［J］. JAAD Case Rep, 2016,2（1）:25⁃27. doi: 10.1016/j.jdcr.2015.12.006.
［29］	Verheyden MJ, Bilgic A, Murrell DF. A systematic review of drug⁃induced pemphigoid［J］. Acta Derm Venereol, 2020. doi: 10.2340/00015555⁃3457.
［30］	Ho PH, Tsai TF. Development of bullous pemphigoid during secukinumab treatment for psoriasis［J］. J Dermatol, 2017,44（9）:e220⁃e221. doi: 10.1111/1346⁃8138.13909.
［31］	Onsun N, Sallahoglu K, Dizman D, et al. Bullous pemphigoid during ustekinumab therapy in a psoriatic patient［J］. Eur J Dermatol, 2017,27（1）:81⁃82. doi: 10.1684/ejd.2016.2888.
［32］	Kamata M, Asano Y, Shida R, et al. Secukinumab decreased circulating anti⁃BP180⁃NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid［J］. J Dermatol, 2019,46（6）:e216⁃e217. doi: 10.1111/1346⁃8138.14760.
［33］	Waki Y, Kamiya K, Komine M, et al. A case of anti⁃laminin γ1 （p200） pemphigoid with psoriasis vulgaris successfully treated with apremilast［J］. Eur J Dermatol, 2018,28（3）:413⁃414. doi: 10.1684/ejd.2018.3280.
［34］	Balighi K, Daneshpazhooh M, Mahmoudi H, et al. Switching from pemphigus vulgaris to psoriasis: a rare report of three cases［J］. Int J Dermatol, 2020,59（5）:e144⁃e146. doi: 10.1111/ijd. 14823.
［35］	Daulat S, Detweiler JG, Pandya AG. Development of pemphigus vulgaris in a patient with psoriasis treated with etanercept［J］. J Eur Acad Dermatol Venereol, 2009,23（4）:483⁃484. doi: 10.1111/ j.1468⁃3083.2008.02929.x.

[1]	He Xie, Li Yuzhen. Targeting the JAK-STAT signaling pathway in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 273-278.
[2]	Sun Yujiao, Wang Jianbo, Duan Ziyu, Dou Jinfa, Li Yan, Li Jianguo, Zhang Shoumin. Detection of ATP2C1 gene mutations in a family with generalized familial benign chronic pemphigus [J]. Chinese Journal of Dermatology, 2023, 0(3): 20210927-e20210927.
[3]	Ruan Shifan, Zhang Peng, Lin Tingting, Luo Renwei, Bao Siyi, Xue Chenyao, Tong Zequn, Zhang Liangliang, Gong Ting, Ji Chao, . Correlations between psoriasis vulgaris and dyslipidemia [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220322-e20220322.
[4]	Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents [J]. Chinese Journal of Dermatology, 2023, 56(3): 191-203.
[5]	Zhou Jian, Yu Chen, Wang Gang. Clinical efficacy and safety of secukinumab in the treatment of 13 cases of refractory localized pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 247-251.
[6]	Hu Kun, Yang Jing, Wang Qiaolin, Chen Junchen, Zhang Mi, Zhu Wu, Zhang Bin, Dou Guanshen, Wendong Chen, Kuang Yehong. Real-world short-term treatment effects of Ixekizumab in Chinese patients with psoriasis: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(3): 210-215.
[7]	Wan Li, Hu Bin, Luo Hongyu, Fang Meizhen, Han Lijuan, Chen Qiang, Zhou Xiaoyong, Chen Liuqing, Chen Jinbo. Clinical characteristics and treatment of eight cases of pemphigus/bullous pemphigoid complicated by herpes simplex virus infection [J]. Chinese Journal of Dermatology, 2023, 56(3): 229-233.
[8]	Chen Lianghong, Sun Yan, Wang Jingyu, Wu Yan. Benvitimod for the treatment of dermatoses [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210875-e20210875.
[9]	Yang Qi, Zheng Jie. Effect of biologics on cardiovascular comorbidities of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(2): 165-169.
[10]	Huang He, Zhang Xuejun. Application of the interleukin-23 inhibitor guselkumab in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(2): 181-184.
[11]	Wang Zhaoyang, Xiang Xin, Chen Yunliu, Miao Chaoyang, Zhao Xinrong, Zhang Zhenhua, Liu Yuanxiang, Ma Lin, Xu Zigang. Comparison of efficacy and safety of biologics versus methotrexate in the treatment of severe pediatric plaque psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(2): 112-117.
[12]	Yang Ying, Guo Qing, Hou Suchun, Min Xue, Tian Jiabin, Qiao Zhuhui, Lin Jialin, Wang Xiaofei, Wu Lantuya, Zhang Zhenying, Li Zhengfeng, Wang Bin, Liu Xiaoming. COVID-19 vaccination status and its impact on psoriatic lesions in patients with psoriasis treated with biologics: a single-center cross-sectional study [J]. Chinese Journal of Dermatology, 2023, 56(1): 59-63.
[13]	Cao Miao, Chong Shan, Wang Mingyue. Effect of different immersion bath methods on the healing of skin lesions in patients with pemphigus [J]. Chinese Journal of Dermatology, 2023, 56(1): 49-53.
[14]	Xiao Chunying, Wang Gang. Roles of Langerhans cells in psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(9): 830-834.
[15]	Zheng Jiayuan, Yu Bingqian, Chen Xianxia, Luo Zhicheng. Characteristics of pruritus in adult patients with psoriasis vulgaris and its effect on quality of life [J]. Chinese Journal of Dermatology, 2022, 55(9): 790-794.

Correlation between autoimmune bullous diseases and psoriasis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［35］

Related Articles 15

Metrics

Comments

Recommended 10